[ad_1] CNBC’s Jim Cramer said Tuesday that Elon Musk’s disclosure that he takes prescription ketamine for depression was courageous and “saved a lot of people from killing themselves.” “I defend … Read More
[ad_1] Vertiv Holdings : The data center equipment maker, whose shares have roughly quadrupled over the past year, issued guidance that didn’t live up to Wall Street’s lofty expectations. However, … Read More
[ad_1] Club holding Eli Lilly is expecting to get approval for its Alzheimer’s treatment in the coming weeks, but investors looking for immediate financial success should temper their expectations. On … Read More
[ad_1] CNBC’s Jim Cramer called out General Electric as a winner in the industrial sector for the strides it’s making in nuclear power. GE’s Verona Nuclear Fuel business said Wednesday … Read More
[ad_1] Wall Street liked what it saw from GE Healthcare and Eli Lilly in their earnings reports, leading to a round of well-deserved price target bumps for the Club stocks. … Read More
[ad_1] Clorox – The consumer products giant saw a huge earnings beat. It’s also rebounding from last year’s cyberattack. “Things are back online, and there’s tremendous demand for their product,” … Read More
[ad_1] Benchmark gauges notched all-time highs as stocks charged through a busy earnings season. [ad_2] Source link
[ad_1] As the old Wall Street adage goes, health care tends to underperform the stock market in presidential election years — and in recent cycles, that’s been true. But, there’s … Read More
[ad_1] We’re making our first Bullpen update of 2024. The Bullpen is a collection of stocks identified by the CNBC Investing Club team as having the potential to join Jim … Read More
[ad_1] Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should … Read More
